



NAVILYST MEDICAL SHOWCASES FOUR NEW PRODUCTS AT ONS

Products Include New Power Injectable Port and Safety Infusion Set

MARLBOROUGH, MA – April 21, 2009 – Navilyst Medical manufacturer and global marketer of vascular access and fluid management devices is pleased to celebrate its continued commitment to oncology nurses as evidenced by the debut of four new products. These new products are designed to contribute to a hospital's compliance with OSHA regulations, CDC guidelines, as well as the Joint Commission Hospital Patient Safety Goals.

The new offerings expand Navilyst Medical's popular vascular access device product lines and can contribute to a hospital's infection prevention program. The new products will be featured at Booth 340/241 at the upcoming Annual Oncology Nursing Society Congress in San Antonio, Texas.

New Xcela® Power Injectable Ports:

Port catheter systems are implanted in over 300,000 patients annually in the U.S. to provide a means for long-term delivery of fluids and medications including chemotherapy. For those who value the benefits of power injectability, Navilyst Medical's new Xcela Power Injectable Ports offer the widest array of port options to satisfy the demands of physician preferences and patient characteristics. The titanium Xcela Ports, available in standard and low profile sizes, offer durability and reduced size for ease of implantation and patient comfort. The plastic Xcela Ports are light weight for patient comfort and offer reduced imaging artifact. Finally, the plastic/titanium hybrid port design option combines the durability of titanium with the light weight and radiolucence of plastic. All designs have a 5mL/sec at 300 psi infusion rating for use in contrast imaging procedures. Xcela Ports are compatible with the Company's new EZ Huber® Safety Infusion Set.

New EZ Huber® Safety Infusion Set:

Navilyst Medical's new EZ Huber Safety Infusion Set has a unique dual-action safety mechanism designed to reduce the risk of bloodborne pathogen exposure that threatens clinician safety and is a significant cost to the healthcare system. One safety feature shields the tip of the needle after the needle is withdrawn from the patient to prevent accidental needle sticks. The second safety feature is a protective cover that surrounds the entire needle after withdrawal to reduce exposure to aerosolized or splattered infusion fluids and blood. The EZ Huber Safety Infusion Set is compatible with Navilyst Medical's new Xcela® Power Injectable Port and is rated for up to 5mL/sec at 300 psi for contrast-

enhanced CT imaging procedures. Approximately 10 million Huber Needle Infusion Sets are used annually in the U.S. to provide access to implanted port catheters.

New 3 French PICC with PASV® Valve Technology

Navilyst Medical has added a 3 French diameter Vaxcel® PICC with PASV Technology to its growing Peripherally Inserted Central Catheter product line. The 3 F catheter significantly expands the application of PASV Technology, particularly in pediatric and elderly patient populations, two patient groups that tend to have increased risk of infection due to immature or weakened immune systems. Navilyst Medical's catheters with proprietary PASV Valve Technology have been shown to reduce rates of catheter occlusions and catheter-related bloodstream infections. Effective October 1, 2008, U.S. hospitals are now cost accountable for certain medical errors and preventable medical care complications, including catheter-related bloodstream infections. At an estimated \$100,000 per event which includes increased diagnostic and therapeutic costs, and increased length of hospitalization, reducing the rate of hospital-acquired catheter-related infections has become a top priority for hospital administrators and hospital infection control teams nationwide.

More Customized PICC Convenience Kits:

Navilyst Medical's market-leading offering of customized Peripherally Inserted Central Catheter (PICC) kits manufactured by Navilyst Medical's Glens Falls, NY facility has been expanded. These enhancements include the new Xcela® Power Injectable PICC and a wider array of PICC insertion accessories and packaging. The market focus for the PICC Convenience Kitting program is on the bedside placement segment which accounts for over two-thirds of the approximately two million PICCs that are sold in the U.S. annually. The program provides clinicians and hospitals the catheter and accessory choices they require for a procedure that is efficient and conducive to reducing the risk of accidental needlesticks (OSHA) and infections (CDC and Joint Commission). This also reduces costs from unnecessary supplies. These PICC Convenience Kits can be ordered with Navilyst Medical's proprietary PASV® Valve catheters which have been shown to reduce rates of catheter occlusions and infections— another asset as hospitals address the reimbursement restrictions by Centers for Medicare and Medicaid Services (CMS) for preventable complications which include catheter-related bloodstream infections.

About Navilyst Medical

Navilyst Medical, headquartered in Marlborough, MA, was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units. Its breakthrough devices, including the PASV® Valve Technology and world-leading NAMIC® Fluid Management products, help hospitals to achieve safe, favorable outcomes for patients. The Company distributes its products worldwide and has its lead U.S. manufacturing facility in Glens Falls, NY. The name Navilyst combines the navi- of navigation and the -lyst of catalyst, encompassing how a leading medical technology enterprise drives industry-changing innovation. For more information, please visit: www.navilystmedical.com.

FORWARD-LOOKING STATEMENTS: This Release contains forward-looking statements, including statements regarding development of Navilyst Medical's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

EZ Huber is a registered trademark of Kerr Marketing

CONTACT: Kerri Connors, Navilyst Medical

Phone: (508) 658 7962; Email: kerri.connors@navilyst.com